Vitamin E and selenium don't prevent polyps that can lead to colorectal cancer

December 19, 2016

Eight years ago, results from a landmark cancer prevention trial run by SWOG showed that a daily dose of vitamin E and selenium did not prevent prostate cancer. In fact, the Selenium and Vitamin E Cancer Prevention Trial (SELECT) showed that vitamin E supplementation increased the risk of prostate cancer in healthy men.

Now, a SWOG review of ancillary SELECT results definitively shows that these two antioxidants also don't prevent colorectal adenomas - polyps that are the premalignant precursors to most colorectal cancers. Results are published in Cancer Prevention Research.

"The message to the public is this: Vitamin E and selenium will not prevent colorectal adenomas, which are surrogates for colorectal cancer," said Dr. Peter Lance, lead author of the journal article and deputy director of the University of Arizona Cancer Center. "We have no evidence that these supplements work to prevent cancer."

Despite the billions spent in the United States each year on supplements, there is scant evidence they prevent cancer. According to the National Cancer Institute, which funds SWOG through its National Clinical Trials Network (NCTN) and NCI Community Oncology Research Program (NCORP), results from nine randomized trials did not provide evidence that antioxidant supplements are beneficial in primary . An in-depth review conducted for the United States Preventive Services Task Force likewise found no clear evidence of benefit.

"There's a whole industry that has people dosing themselves thinking that vitamins will keep them healthy," Lance said. "But we have little evidence that they protect against ."

To arrive at their conclusions, Lance and his SWOG team used data from SELECT, a prevention trial that enrolled an astonishing 35,533 healthy men - 21 percent men of color - in just 33 months at 427 study sites the United States, Canada, and Puerto Rico. Men were randomized into four groups. Some took a daily dose of vitamin E, others a dose of selenium, others took both antioxidants, and the rest took a placebo only.

A substantial number of SELECT participants incidentally underwent a lower endoscopy - colonoscopy or sigmoidoscopy - as part of their usual clinical care while taking part in the trial. In an ancillary study, Lance and his team went back into the SELECT data to review the lower endoscopy and pathology reports. They were able to evaluate information on 6,546 participants who received the procedure as part of SELECT, and found that 2,286 had more than one polyp detected by cameras used in the procedures. A statistical analysis showed that the occurrence of one or more premalignant polyps was about the same among men, regardless of whether men were taking selenium or vitamin E, alone or together, or double placebo.

What makes these results definitive, Lance said, is that SELECT was so large and was a randomized controlled study - a design that reduces bias and is considered the gold standard in clinical research.

Lance led another University of Arizona Cancer Center team that has just published similar results from a separate randomized trial of selenium and celecoxib. In December 2016, in the Journal of the National Cancer Institute, the team reported that didn't prevent colorectal adenomas - and was associated with increased risk for Type 2 diabetes.

Explore further: Team questions safety, efficacy of selenium and colorectal cancer risk

Related Stories

Team questions safety, efficacy of selenium and colorectal cancer risk

October 14, 2016
A 12-year study led by a team of University of Arizona Cancer Center researchers is bringing into question the safety and efficacy of selenium, a popular nutritional supplement touted to combat and reduce the risk of colorectal ...

Vitamin E, selenium supplements unlikely to effect age-related cataracts in men

September 18, 2014
Taking daily supplements of selenium and/or vitamin E appears to have no significant effect on the development of age-related cataracts in men, writes Author William G. Christen, Sc.D., of Brigham & Women's Hospital and Harvard ...

Selenium and vitamin E supplementation over recommended dietary intake may raise prostate cancer risk

February 21, 2014
A multi-center study led by Fred Hutchinson Cancer Research Center has found that high-dose supplementation with both the trace element selenium and vitamin E increase the risk of high-grade prostate cancer. But importantly, ...

Use of vitamin E associated with increased risk of prostate cancer

October 11, 2011
In a trial that included about 35,000 men, those who were randomized to receive daily supplementation with vitamin E had a significantly increased risk of prostate cancer, according to a study in the October 12 issue of JAMA.

Risk factors for prostate cancer aren't what we think, study shows

October 31, 2016
When it comes to prostate cancer biopsies, risk and reality don't always match up, according to research published online today in the Journal of Clinical Oncology.

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.